Live Breaking News & Updates on Lifesci At Acquisition Ii Corp

Search jobs
07-May-2021
Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future
Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing
Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research
$80 million via LifeSci Acquisition II Corp., a special purpose acquisition company with no public warrants
$200 million via fully committed and upsized PIPE from leading institutional and strategic investors including Redmile Group; funds and accounts managed by BlackRock; Casdin Capital; dRx Capital (Novartis Pharma AG); LifeSci Venture Partners; Lux Capital; Mubadala Capital, the asset management arm of Mubadala Investment Company; Perceptive Advisors; PPD; P ....

New York , United States , Nina Gill , David Coman , Andrew Mcdonald , Margie Kooman , Diversity In Clinical Research Foundation , Redmile Group , Latham Watkins , Lifesci At Acquisition Ii Corp , Lifesci Acquisition Ii Corp , Mubadala Investment Company , Exchange Commission , Lifesci Capital , Surveyor Capitala Citadel Company , Lifesci Acquisition , Casdin Capital , Novartis Pharma , Lifesci Venture Partners , Lux Capital , Mubadala Capital , Perceptive Advisors , Pura Vida Investments , Samsara Biocapital , Surveyor Capital , Citadel Company ,